论文部分内容阅读
目的探讨黄葵胶囊降低特发性膜性肾病蛋白尿的疗效。方法收集2013年5月至2016年1月病理确诊为膜性肾病,24 h蛋白尿<3.5 g的67例患者随机分为两组,研究组35例,对照组32例。对照组使用单纯血管紧张素转化酶抑制剂(ACEI)类药物治疗,研究组采用黄葵胶囊联合ACEI治疗。比较两组患者蛋白尿的变化情况。结果治疗前,研究组24 h尿蛋白为(3.26±0.37)g,对照组为(3.19±0.29)g,两组比较差异未见统计学意义(P>0.05);治疗后8周,研究组和对照组24 h尿蛋白值分别为(1.31±0.11)、(2.60±0.26)g,前者明显低于后者,差异有统计学意义(P<0.05)。结论采用黄葵胶囊联合ACEI降低特发性膜性肾病患者蛋白尿效果显著,值得在临床上推广使用。
Objective To investigate the efficacy of Huang Kui Capsule in reducing proteinuria of idiopathic membranous nephropathy. Methods 67 patients with membranous nephropathy and 24 h proteinuria <3.5 g were collected from May 2013 to January 2016. They were randomly divided into two groups: study group 35 cases and control group 32 cases. The control group was treated with angiotensin-converting enzyme inhibitor (ACEI). The study group was treated with Huang Kui capsule combined with ACEI. The changes of albuminuria in two groups were compared. Results Before treatment, urinary protein in 24 h of study group was (3.26 ± 0.37) g and (3.19 ± 0.29) g in control group, there was no significant difference between the two groups (P> 0.05). After 8 weeks of treatment, (1.31 ± 0.11) and (2.60 ± 0.26) g respectively, the former was lower than the latter, the difference was statistically significant (P <0.05). Conclusion The use of Huang Kui capsules combined with ACEI reduce idiopathic membranous nephropathy in patients with proteinuria significant effect, it is worth promoting in clinical use.